These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

294 related items for PubMed ID: 33360574

  • 1. Hit-to-lead optimization on aryloxybenzamide derivative virtual screening hit against SIRT.
    Yagci S, Gozelle M, Kaya SG, Ozkan Y, Aksel AB, Bakar-Ates F, Dundar Y, Eren G.
    Bioorg Med Chem; 2021 Jan 15; 30():115961. PubMed ID: 33360574
    [Abstract] [Full Text] [Related]

  • 2. Pharmacophore modeling and virtual screening studies to identify novel selective SIRT2 inhibitors.
    Eren G, Bruno A, Guntekin-Ergun S, Cetin-Atalay R, Ozgencil F, Ozkan Y, Gozelle M, Kaya SG, Costantino G.
    J Mol Graph Model; 2019 Jun 15; 89():60-73. PubMed ID: 30870650
    [Abstract] [Full Text] [Related]

  • 3. Design, synthesis and structure-activity relationship studies of novel sirtuin 2 (SIRT2) inhibitors with a benzamide skeleton.
    Sakai T, Matsumoto Y, Ishikawa M, Sugita K, Hashimoto Y, Wakai N, Kitao A, Morishita E, Toyoshima C, Hayashi T, Akiyama T.
    Bioorg Med Chem; 2015 Jan 15; 23(2):328-39. PubMed ID: 25515955
    [Abstract] [Full Text] [Related]

  • 4. Design, synthesis, in-vitro evaluation and molecular docking studies of novel indole derivatives as inhibitors of SIRT1 and SIRT2.
    Manjula R, Gokhale N, Unni S, Deshmukh P, Reddyrajula R, Srinivas Bharath MM, Dalimba U, Padmanabhan B.
    Bioorg Chem; 2019 Nov 15; 92():103281. PubMed ID: 31561106
    [Abstract] [Full Text] [Related]

  • 5. Structure activity study of S-trityl-cysteamine dimethylaminopyridine derivatives as SIRT2 inhibitors: Improvement of SIRT2 binding and inhibition.
    Radwan MO, Ciftci HI, Ali TFS, Koga R, Tateishi H, Nakata A, Ito A, Yoshida M, Fujita M, Otsuka M.
    Bioorg Med Chem Lett; 2020 Oct 01; 30(19):127458. PubMed ID: 32755678
    [Abstract] [Full Text] [Related]

  • 6. Hit evaluation results in 5-benzyl-1,3,4-thiadiazole-2-carboxamide based SIRT2-selective inhibitor with improved affinity and selectivity.
    Gozelle M, Kaya SG, Aksel AB, Ozkan E, Bakar-Ates F, Ozkan Y, Eren G.
    Bioorg Chem; 2022 Jun 01; 123():105746. PubMed ID: 35358824
    [Abstract] [Full Text] [Related]

  • 7. Identification of a sirtuin 3 inhibitor that displays selectivity over sirtuin 1 and 2.
    Galli U, Mesenzani O, Coppo C, Sorba G, Canonico PL, Tron GC, Genazzani AA.
    Eur J Med Chem; 2012 Sep 01; 55():58-66. PubMed ID: 22835719
    [Abstract] [Full Text] [Related]

  • 8. Synthesis and evaluation of novel benzimidazole derivatives as sirtuin inhibitors with antitumor activities.
    Yoon YK, Ali MA, Wei AC, Choon TS, Osman H, Parang K, Shirazi AN.
    Bioorg Med Chem; 2014 Jan 15; 22(2):703-10. PubMed ID: 24387981
    [Abstract] [Full Text] [Related]

  • 9. The discovery of a highly selective 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one SIRT2 inhibitor that is neuroprotective in an in vitro Parkinson's disease model.
    Di Fruscia P, Zacharioudakis E, Liu C, Moniot S, Laohasinnarong S, Khongkow M, Harrison IF, Koltsida K, Reynolds CR, Schmidtkunz K, Jung M, Chapman KL, Steegborn C, Dexter DT, Sternberg MJ, Lam EW, Fuchter MJ.
    ChemMedChem; 2015 Jan 15; 10(1):69-82. PubMed ID: 25395356
    [Abstract] [Full Text] [Related]

  • 10. Synthesis of certain benzothieno[3,2-d]pyrimidine derivatives as a selective SIRT2 inhibitors.
    Khalil NA, Ahmed EM, Zaher AF, El-Zoghbi MS, Sobh EA.
    Eur J Med Chem; 2020 Feb 01; 187():111926. PubMed ID: 31812033
    [Abstract] [Full Text] [Related]

  • 11. X-ray crystal structure guided discovery of new selective, substrate-mimicking sirtuin 2 inhibitors that exhibit activities against non-small cell lung cancer cells.
    Yang LL, Wang HL, Zhong L, Yuan C, Liu SY, Yu ZJ, Liu S, Yan YH, Wu C, Wang Y, Wang Z, Yu Y, Chen Q, Li GB.
    Eur J Med Chem; 2018 Jul 15; 155():806-823. PubMed ID: 29957526
    [Abstract] [Full Text] [Related]

  • 12. Virtual screening approach of sirtuin inhibitors results in two new scaffolds.
    Kokkonen P, Kokkola T, Suuronen T, Poso A, Jarho E, Lahtela-Kakkonen M.
    Eur J Pharm Sci; 2015 Aug 30; 76():27-32. PubMed ID: 25936698
    [Abstract] [Full Text] [Related]

  • 13. Recent advances in inhibitors of sirtuin1/2: an update and perspective.
    Zhou Z, Ma T, Zhu Q, Xu Y, Zha X.
    Future Med Chem; 2018 Apr 01; 10(8):907-934. PubMed ID: 29642711
    [Abstract] [Full Text] [Related]

  • 14. Identification of a Selective SIRT2 Inhibitor and Its Anti-breast Cancer Activity.
    Shah AA, Ito A, Nakata A, Yoshida M.
    Biol Pharm Bull; 2016 Apr 01; 39(10):1739-1742. PubMed ID: 27725455
    [Abstract] [Full Text] [Related]

  • 15. SIRT inhibitors induce cell death and p53 acetylation through targeting both SIRT1 and SIRT2.
    Peck B, Chen CY, Ho KK, Di Fruscia P, Myatt SS, Coombes RC, Fuchter MJ, Hsiao CD, Lam EW.
    Mol Cancer Ther; 2010 Apr 01; 9(4):844-55. PubMed ID: 20371709
    [Abstract] [Full Text] [Related]

  • 16. Enzymatic and Biological Characterization of Novel Sirtuin Modulators against Cancer.
    Carafa V, Poziello A, Della Torre L, Giovannelli P, Di Donato M, Safadeh E, Yu Z, Baldi A, Castoria G, Tomaselli D, Mai A, Rotili D, Nebbioso A, Altucci L.
    Int J Mol Sci; 2019 Nov 12; 20(22):. PubMed ID: 31726691
    [Abstract] [Full Text] [Related]

  • 17. Discovery of New SIRT2 Inhibitors by Utilizing a Consensus Docking/Scoring Strategy and Structure-Activity Relationship Analysis.
    Huang S, Song C, Wang X, Zhang G, Wang Y, Jiang X, Sun Q, Huang L, Xiang R, Hu Y, Li L, Yang S.
    J Chem Inf Model; 2017 Apr 24; 57(4):669-679. PubMed ID: 28301150
    [Abstract] [Full Text] [Related]

  • 18. Discovery of bicyclic pyrazoles as class III histone deacetylase SIRT1 and SIRT2 inhibitors.
    Therrien E, Larouche G, Nguyen N, Rahil J, Lemieux AM, Li Z, Fournel M, Yan TP, Landry AJ, Lefebvre S, Wang JJ, MacBeth K, Heise C, Nguyen A, Besterman JM, Déziel R, Wahhab A.
    Bioorg Med Chem Lett; 2015 Jun 15; 25(12):2514-8. PubMed ID: 25971769
    [Abstract] [Full Text] [Related]

  • 19. Direct Comparison of SIRT2 Inhibitors: Potency, Specificity, Activity-Dependent Inhibition, and On-Target Anticancer Activities.
    Spiegelman NA, Price IR, Jing H, Wang M, Yang M, Cao J, Hong JY, Zhang X, Aramsangtienchai P, Sadhukhan S, Lin H.
    ChemMedChem; 2018 Sep 19; 13(18):1890-1894. PubMed ID: 30058233
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.